MedTech Dive October 10, 2024
Nick Paul Taylor

The funding will support the pivotal trial, premarket approval application and initial commercial launch of a system that could interrupt or change the transmission of pain signals to the brain.

Dive Brief:

  • Shiratronics has raised $66 million to fund a pivotal trial of an implantable neuromodulation treatment for chronic migraine, the company said Wednesday.
  • The trial is designed to evaluate the safety and effectiveness of the system in patients with treatment-resistant chronic migraine who have failed current medical therapies.
  • The Series B funding will also help support the premarket approval process for the device and the initial commercial launch.

Dive Insight:

Researchers have studied occipital nerve stimulation for decades and generated clinical evidence of efficacy against migraine when...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Investments, Medical Devices, Trends
Bariatric operations & GLP-1s: What to know
Device maker files for bankruptcy: 4 notes
Harnessing AI to revolutionize healthcare: A conversation with Huma’s Dan Vahdat
GE HealthCare to create new Theranostics Center of Excellence in Europe
WellSky Acquires Bonafide to Enhance DME/HME Solutions

Share This Article